The startup develops targeted therapeutics for genetically associated kidney disorders, including autosomal dominant and recessive polycystic kidney disease and Fabry disease. By focusing on these specific conditions, the company aims to provide safe and effective treatment options for patients suffering from these genetic diseases.
Funding
$63.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetically linked kidney disorders, such as autosomal dominant and recessive polycystic kidney disease and Fabry disease, lack effective and targeted therapeutic options. The complexity of glycolipid metabolism in these diseases presents challenges in developing treatments that can safely and effectively address the underlying causes.
Solution
AceLink Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for diseases of glycolipid metabolism, particularly genetically associated kidney disorders. Their lead programs include glucosylceramide synthase (GCS) inhibitors and NRF2 activators designed to address the root causes of these diseases. AL1211, a non-brain penetrant GCS inhibitor, is currently in Phase 2 trials for Fabry disease and is also being developed for type I Gaucher disease. AL0804 is a brain-penetrant GCS inhibitor under development for neuronopathic glycolipid storage diseases. AL1311, a potent NRF2 activator, is being developed for autosomal dominant polycystic kidney disease (ADPKD).
Target Audience
The primary target audience includes patients suffering from genetically associated kidney disorders such as Fabry disease, Gaucher disease, and autosomal dominant polycystic kidney disease, as well as the physicians who treat them.
Features
- AL1211: Non-brain penetrant glucosylceramide synthase (GCS) inhibitor in Phase 2 trials for Fabry disease and development for type I Gaucher disease.
- AL0804: Brain-penetrant GCS inhibitor for neuronopathic glycolipid storage diseases, including Gaucher disease (Types II and III) and GM2 gangliosidosis.
- AL1311: Potent NRF2 activator in development for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Focus on modulating glycolipid biology to address the underlying causes of genetic diseases.